DexCom (DXCM) Eyes Deeper Correction Toward $44.11–$20.95 Zone

DexCom Inc., (DXCM) is a medical device company, that focuses on the design, development & commercialization of glucose monitoring systems globally. It comes under Healthcare sector & trades as “DXCM” ticker at Nasdaq.

DexCom Inc., (DXCM) is a medical device company, that focuses on the design, development & commercialization of glucose monitoring systems globally. It comes under Healthcare sector & trades as “DXCM” ticker at Nasdaq.

The DXCM favors double correction in weekly from November-2021 high discussed in last article few months ago. It favors weakness started from 2.17.2025 high & expect downside into $44.11 or lower.

DXCM - Elliott Wave Latest Weekly View:

In weekly, it ended ((I)) impulse at $164.86 high in November-2021 & now correcting in ((II)). Within ((I)), it ended (I) at $25.82 high in September-2015 & (II) at $10.65 low in September-2017. Above there, it placed (III) as extended move at $114.06 high, (IV) at $76.41 low & finally ended (V) at $164.86 high as ((I)). Below November-2021 high, it favors downside in 7 swings pullback & expect short term bounce in 3, 7 or 11 swings to fail below 7.28.2025 high.

DXCM - Elliott Wave View From 3.31.2025:

Within ((II)) pullback, it ended (w) at $66.89 low in May-2022 & (x) connector at $142 high in March-2024. Both the moves are 3 swings. It already showing lower low sequence in ((II)) correction, favoring (y) down. Below (x) high, it ended w at $62.34 low, x at $93.25 high & favor downside in y leg. The y is further subdivided in ((A)) ended at $57.52 low, ((B)) at $89.98 high & favoring downside in ((c)) of y of (y). It expects weakness against July-2025 high to extend downside in to $44.11 - $20.95 area or even lower. The sellers can enter the set up in 3, 7 or 11 swings corrective bounce at extreme area for targeting weekly extreme area.

Source: https://elliottwave-forecast.com/stock-market/dxcm-eyes-deeper-correction-toward-44-1-20-9/

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.

STOCKS IN THIS BLOG POST

Comments